Lipoprotein-associated phospholipase A2 (Lp-PLA2): Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
Latest revision as of 19:06, 4 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that can modify low-density lipoproteins and may be involved in atherogenesis and the risk of coronary artery disease. In a nested case-control study, patients in the highest quintile of Lp-PLA2 levels had nearly twice the odds of coronary events compared with patients in the lowest quintile.